These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Karakousis PC, Moore RD, Chaisson RE. Lancet Infect Dis; 2004 Sep; 4(9):557-65. PubMed ID: 15336223 [Abstract] [Full Text] [Related]
4. [Diagnosis and treatment of tuberculosis or Mycobacterium avium-intracellulare complex infection in HIV-infected patients]. Shirasaka T. Kekkaku; 2007 Nov; 82(11):845-8. PubMed ID: 18078110 [Abstract] [Full Text] [Related]
7. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. López-Palomo C, Martín-Zamorano M, Benítez E, Fernández-Gutiérrez C, Guerrero F, Rodríguez-Iglesias M, Girón-González JA. J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752 [Abstract] [Full Text] [Related]
13. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Zeller V, Truffot C, Agher R, Bossi P, Tubiana R, Caumes E, Jouan M, Bricaire F, Katlama C. Clin Infect Dis; 2002 Mar 01; 34(5):662-7. PubMed ID: 11810599 [Abstract] [Full Text] [Related]
14. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. Aberg JA, Williams PL, Liu T, Lederman HM, Hafner R, Torriani FJ, Lennox JL, Dube MP, MacGregor RR, Currier JS, AIDS Clinical Trial Group 393 Study Team. J Infect Dis; 2003 Apr 01; 187(7):1046-52. PubMed ID: 12660918 [Abstract] [Full Text] [Related]
15. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Graham NM, Galai N, Nelson KE, Astemborski J, Bonds M, Rizzo RT, Sheeley L, Vlahov D. Arch Intern Med; 1996 Apr 22; 156(8):889-94. PubMed ID: 8774208 [Abstract] [Full Text] [Related]
16. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. Ives NJ, Gazzard BG, Easterbrook PJ. J Infect; 2001 Feb 22; 42(2):134-9. PubMed ID: 11531320 [Abstract] [Full Text] [Related]